Candida auris in Greek healthcare facilities: Active surveillance results on first cases and outbreaks from eleven hospitals within Attica region - 04/04/24
, Georgia Vrioni b, Sofia Hatzianastasiou c, Malvina Lada d, Maria Martsoukou e, Nikolaos V. Sipsas f, Maria Chini g, Vasiliki Baka h, Eleni Kafkoula h, Aikaterini Masgala i, Maria Pirounaki j, Christos Michailidis k, Georgios Chrysos l, Olympia Zarkotou m, Vasiliki Mamali m, Vasileios Papastamopoulos n, Georgios Saroglou o, Spyros Pournaras p, Joseph Meletiadis p, Ioannis Karakasiliotis q, Stefanos Karachalios r, Stavroula Smilakou s, Vasiliki Skandami t, Maria Orfanidou u, Athina Argyropoulou v, Athanassios Tsakris b, Flora Kontopidou wthe Candida auris study collaborative group
Abstract |
Background |
Candida auris was sporadically detected in Greece until 2019. Thereupon, there has been an increase in isolations among inpatients of healthcare facilities.
Aim |
We aim to report active surveillance data on MALDI-TOF confirmed Candida auris cases and outbreaks, from November 2019 to September 2021.
Methods |
A retrospective study on hospital-based Candida auris data, over a 23-month period was conducted, involving 11 hospitals within Attica region. Antifungal susceptibility testing and genotyping were conducted. Case mortality and fatality rates were calculated and p-values less than 0.05 were considered statistically significant. Infection control measures were enforced and enhanced.
Results |
Twenty cases with invasive infection and 25 colonized were identified (median age: 72 years), all admitted to hospitals for reasons other than fungal infections. Median hospitalisation time until diagnosis was 26 days. Common risk factors among cases were the presence of indwelling devices (91.1 %), concurrent bacterial infections during hospitalisation (60.0 %), multiple antimicrobial drug treatment courses prior to hospitalisation (57.8 %), and admission in the ICU (44.4 %). Overall mortality rate was 53 %, after a median of 41.5 hospitalisation days. Resistance to fluconazole and amphotericin B was identified in 100 % and 3 % of tested clinical isolates, respectively. All isolates belonged to South Asian clade I. Outbreaks were identified in six hospitals, while remaining hospitals detected sporadic C. auris cases.
Conclusion |
Candida auris has proven its ability to rapidly spread and persist among inpatients and environment of healthcare facilities. Surveillance focused on the presence of risk factors and local epidemiology, and implementation of strict infection control measures remain the most useful interventions.
Le texte complet de cet article est disponible en PDF.Keywords : Candida auris, Hospital acquired infections, Active surveillance, Emerging pathogen, Antifungal susceptibility, Infection prevention and control measures
Plan
Vol 34 - N° 2
Article 101477- juin 2024 Retour au numéro
Article précédent
- Acquired resistance or tolerance? – in search of mechanisms underlying changes in the resistance profile of Candida albicans and Candida parapsilosis as a result of exposure to methotrexate
- Katarzyna Góralska, Małgorzata Szybka, Filip Franciszek Karuga, Dorota Pastuszak-Lewandoska, Ewa Brzeziańska-Lasota
- Synergistic activity of crocin and crocin loaded in niosomes alone and in combination with fluconazole against Candida albicans isolates: In vitro and in silico study
- Sara Norozipor, Mehdi Bamorovat, Seyyed Amin Ayatollahi Mosavi, Ehsan Salarkia, Sanaz Hadizadeh, Fatemeh Sharifi, Ali Karamoozian, Mehdi Ranjbar, Setareh Agha Kuchak Afshari
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?